Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNparotis
2024-514233-37-00Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium Ga 68 tilmanocept in Parotid gland carcinoma, sponsored by University Medical Center Utrecht. Primary endpoint: Feasibility of sentinel lymph node biopsy using 68Ga-tilmanocept PET/CT lymphoscintigraphy. Planned start Jul 2024; status: authorised.
02
Drugs
gallium Ga 68 tilmanocept
03
Conditions
Parotid gland carcinoma
Beyond the preview
Go deeper on 2024-514233-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514233-37-00.